162 related articles for article (PubMed ID: 8811919)
1. A novel method for chemical modification of functional groups other than a carboxyl group in proteins by N-ethyl-5-phenylisooxazolium-3'-sulfonate (Woodward's reagent-K): inhibition of ADP-induced platelet responses involves covalent modification of aggregin, an ADP receptor.
Puri RN; Colman RW
Anal Biochem; 1996 Sep; 240(2):251-61. PubMed ID: 8811919
[TBL] [Abstract][Full Text] [Related]
2. Modulation of platelet responses by 2-[3-(bromo-2-oxopropylthio)]adenosine-5'-diphosphate involves its binding to as well as covalent modification of an ADP-receptor, aggregin.
Puri RN; Colman RF; Colman RW
Arch Biochem Biophys; 1997 Jul; 343(1):140-5. PubMed ID: 9210656
[TBL] [Abstract][Full Text] [Related]
3. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin.
Puri RN; Colman RF; Colman RW
Eur J Biochem; 1996 Mar; 236(3):862-70. PubMed ID: 8665907
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP.
Puri RN; Kumar A; Chen H; Colman RF; Colman RW
J Biol Chem; 1995 Oct; 270(41):24482-8. PubMed ID: 7592664
[TBL] [Abstract][Full Text] [Related]
5. Immunoaffinity method to identify aggregin, a putative ADP-receptor in human blood platelets.
Puri RN; Colman RW
Arch Biochem Biophys; 1997 Nov; 347(2):263-70. PubMed ID: 9367534
[TBL] [Abstract][Full Text] [Related]
6. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor.
Puri RN; Colman RW
J Cell Biochem; 1996 Apr; 61(1):97-108. PubMed ID: 8726359
[TBL] [Abstract][Full Text] [Related]
8. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Savi P; Laplace MC; Maffrand JP; Herbert JM
J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
[TBL] [Abstract][Full Text] [Related]
9. ADP-induced platelet activation.
Puri RN; Colman RW
Crit Rev Biochem Mol Biol; 1997; 32(6):437-502. PubMed ID: 9444477
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ADP-induced platelet shape change and aggregation by o-phthalaldehyde: evidence for covalent modification of cysteine and lysine residues.
Puri RN; Colman RW
Arch Biochem Biophys; 1991 May; 286(2):419-27. PubMed ID: 1910292
[TBL] [Abstract][Full Text] [Related]
11. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
12. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
13. Aggregin: a platelet ADP receptor that mediates activation.
Colman RW
FASEB J; 1990 Mar; 4(5):1425-35. PubMed ID: 2407587
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
15. Distinction between glycoprotein IIIa and the 100-kDa membrane protein (aggregin) mediating ADP-induced platelet activation.
Colman RW; Figures WR; Wu QX; Chung SY; Morinelli TA; Tuszynski GP; Colman RF; Niewiarowski S
Arch Biochem Biophys; 1988 Apr; 262(1):298-306. PubMed ID: 3281588
[TBL] [Abstract][Full Text] [Related]
16. ADP-mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb.
Teng CM; Kang YF; Chang YL; Ko FN; Yang SC; Hsu FL
Thromb Haemost; 1997 Mar; 77(3):555-61. PubMed ID: 9066010
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.
Mills DC; Puri R; Hu CJ; Minniti C; Grana G; Freedman MD; Colman RF; Colman RW
Arterioscler Thromb; 1992 Apr; 12(4):430-6. PubMed ID: 1558834
[TBL] [Abstract][Full Text] [Related]
18. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
[TBL] [Abstract][Full Text] [Related]
19. Two mechanisms for inhibition of ADP-induced platelet shape change by 5'-p-fluorosulfonylbenzoyladenosine. Conversion to adenosine, and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase.
Mills DC; Figures WR; Scearce LM; Stewart GJ; Colman RF; Colman RW
J Biol Chem; 1985 Jul; 260(13):8078-83. PubMed ID: 2989276
[TBL] [Abstract][Full Text] [Related]
20. Identification of human platelet membrane fibrinogen receptors by immunochemical techniques.
Kornecki E; Tuszynski GP; Niewiarowski S
Haematologia (Budap); 1984; 17(3):387-98. PubMed ID: 6100105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
